Mental Depression
Compass Pathways Achieves Phase 3 Win for Psilocybin in Depression, Yet Stock Tumbles
Compass Pathways; COMP360; psilocybin; Phase 3 trial; depression; treatment-resistant depression; clinical trial; stock decline; investor reaction; FDA
Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline
Draig Therapeutics; $140M Series A; neuropsychiatric drugs; DT-101; depression treatment; AMPA receptor modulator; GABA modulators; biotech funding; Cardiff University; SV Health Investors
Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue
Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones
J&J’s Spravato Surpasses $1 Billion in Revenue for 2024
J&J, Spravato, revenue, 2024, depression treatment, nasal spray
Relmada Therapeutics Considers Strategic Alternatives Following Depression Drug Setbacks
Relmada Therapeutics, depression drug, REL-1017, strategic alternatives, sale, major depressive disorder, NMDA receptor blocker
Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months
CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.
Supernus’ SPN-820 Shows Rapid Symptom Improvement in Major Depressive Disorder
Supernus Pharmaceuticals, SPN-820, Major Depressive Disorder (MDD), Rapid-Acting Depression Treatment, Clinical Trial Results
Intra-Cellular’s Caplyta Achieves Second Phase III Success in Major Depressive Disorder Treatment
Caplyta, Intra-Cellular Therapies, Major Depressive Disorder, Phase III Trial, Lumateperone, Antipsychotic, Depression Treatment
Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial
Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment
Neurocrine Biosciences and Takeda’s Collaborative Drug Shows Promising Results in Phase II Clinical Trial for Depression
Neurocrine Biosciences, Takeda, drug candidate, Phase II clinical trial, depression, promising results.